ES2146240T3 - Agente inmunomodulador y antiinflamatorio. - Google Patents

Agente inmunomodulador y antiinflamatorio.

Info

Publication number
ES2146240T3
ES2146240T3 ES94112427T ES94112427T ES2146240T3 ES 2146240 T3 ES2146240 T3 ES 2146240T3 ES 94112427 T ES94112427 T ES 94112427T ES 94112427 T ES94112427 T ES 94112427T ES 2146240 T3 ES2146240 T3 ES 2146240T3
Authority
ES
Spain
Prior art keywords
agent
diseases
pharmaceutical composition
immunomodulating
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94112427T
Other languages
English (en)
Inventor
Haruo Yoshii
Yuriko Fukata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2146240T3 publication Critical patent/ES2146240T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION PREVE UNA COMPOSICION FARMACEUTICA CON UN NUEVO UNOS FARMACEUTICO QUE CONTIENE UNA GLOBULINA GAMA AÑADIDA DE HISTAINA COMO COMPONENTE EFECTIVO. LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNA GLOBULINA DE GAMA AÑADIDA DE HISTAMINA USADA COMO UN AGENTE DE INMUNOMODULACION, COMO, UN AGENTE SUPRESOR PARA EOSINOFILIO Y AGENTE ANTIINFLAMATORIO, ETC. LA COMPOSICION FARMACEUTICA DE LA PRESENTE INVENCION TIENE UNA ACCION INMUNOMODULADORA QUE ES CLARAMENTE DIFERENTE DE LOS AGENTES INMUNOSUPRESOES CONVENCIONALES. DE ACUERDO, DON DICHA COMPOSICION ES UTIL COMO AGENTE FARMACEUTICO PARA LA TERAPIA DE LAS ENFERMEDADES CON SISTEMA INMUNOLOGICO ANORMAL TAL COMO, POR EJEMPLO REUMATISMO ARTICULAR CRONICO, ERITEMATOSIS DE LUPUS SISTEMICA, ESCLEROSIS MULTIPLE, ETC Y VARIOS TIPOS DE SINDROMES DE INMUNODEFICIENCIA. ADEMAS, LA COMPOSICION FARMACEUTICA DE LA PRESENTE INVENCION TAMBIEN MUESTRA UNA ACCION SUPRESOR SOBRE UNA HIPEREOSOFILIDAD Y PUEDE USARSE COMO UN AGENTETERAPEUTICO PARA ENFERMEDADES INFECCIOSAS, ENFERMEDADES PARASITARIAS, ENFERMEDADES RESPIRATORIAS, ENFERMEDADES AUTOINMUNE Y EOSINOFILIA CAUSADA POR TUMOR MALIGNO, ASI COMO UN AGENTE ANTIINFLAMATORIO EN EL QUE DICHA COMPOSICION ES MUY UTIL.
ES94112427T 1993-08-09 1994-08-09 Agente inmunomodulador y antiinflamatorio. Expired - Lifetime ES2146240T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21804393A JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤

Publications (1)

Publication Number Publication Date
ES2146240T3 true ES2146240T3 (es) 2000-08-01

Family

ID=16713756

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94112427T Expired - Lifetime ES2146240T3 (es) 1993-08-09 1994-08-09 Agente inmunomodulador y antiinflamatorio.

Country Status (9)

Country Link
US (1) US5780026A (es)
EP (1) EP0646376B1 (es)
JP (1) JP3193205B2 (es)
KR (1) KR100275174B1 (es)
CN (3) CN1127983C (es)
AT (1) ATE192655T1 (es)
DE (1) DE69424362T2 (es)
ES (1) ES2146240T3 (es)
TW (1) TW258664B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
IT1278052B1 (it) * 1995-03-14 1997-11-17 Mendes Srl Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JPH0959180A (ja) * 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
JPH10212246A (ja) 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
JP2000143536A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19944122A1 (de) * 1999-09-15 2001-03-29 Wolfgang Loh Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
EP2147679B1 (en) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
WO2004075845A2 (en) * 2003-02-24 2004-09-10 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
WO2008139487A1 (en) * 2007-05-10 2008-11-20 Rajesh Shah Homeopathy-based formulation
JP5564517B2 (ja) 2009-02-20 2014-07-30 ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ グルタチオンをベースとする薬物送達システム
CN102458374A (zh) 2009-05-06 2012-05-16 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5585526A (en) * 1978-12-23 1980-06-27 Nippon Zoki Pharmaceut Co Ltd Remedy for allergic disease
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
US4704273A (en) * 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5244902A (en) * 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) * 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤

Also Published As

Publication number Publication date
CN1121430A (zh) 1996-05-01
TW258664B (es) 1995-10-01
CN1471975A (zh) 2004-02-04
JPH0753406A (ja) 1995-02-28
CN1471974A (zh) 2004-02-04
EP0646376A1 (en) 1995-04-05
EP0646376B1 (en) 2000-05-10
DE69424362T2 (de) 2000-10-19
JP3193205B2 (ja) 2001-07-30
KR950005323A (ko) 1995-03-20
US5780026A (en) 1998-07-14
DE69424362D1 (de) 2000-06-15
CN1127983C (zh) 2003-11-19
ATE192655T1 (de) 2000-05-15
KR100275174B1 (ko) 2000-12-15

Similar Documents

Publication Publication Date Title
ES2146240T3 (es) Agente inmunomodulador y antiinflamatorio.
NO159724C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme imidazo(1,2-a)-pyraziner.
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
MY131458A (en) Pyrolopyrimidine compounds
ES8701496A1 (es) Procedimiento para preparar una sal de 9-(1, 3-dihidroxi-2-propoximetil)-guanina farmaceuticamente aceptable
MY111201A (en) New imidazopyridines
PT705100E (pt) Guanidinas substituidas terapeuticas
IT7928417A0 (it) Composizioni farmaceutiche con esaltazione dell'attivita'terapeutica di cortisonici.
IT1099319B (it) Apparecchiatura e procedimento per l'allineamento delle ruote di autoveicoli
IT8009551A0 (it) E-5-(2-alogenovinil-)-2'deossicitidine, loro metodo di preparazione e loro impiego per il trattamentodi malattie da virus
IT1091051B (it) Procedimento per l'estrusione ad alta riduzione di metalli
NO932377D0 (no) Antivirale forbindelser
IL75805A (en) Pharmaceutical immunosuppressor compositions containing lycorine
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
ATE236615T1 (de) Pharmazeutische zubereitung zur oralen anwendung enthaltend einen histamin-immunoglobulin komplex
IT8023229A0 (it) Procedimento di seperazione o di purificazione di miscele conl'ausilio di un solido assorbente.
EG17890A (en) Improved antiinflammatory compositions and methods
IT8223309A0 (it) Composizione farmaceutica per il trattamento di malattie cardiovascolari.
IL110187A0 (en) 10-Substituted 1,8-dihydroxy-9(10H) anthracenones and pharmaceutical compositions containing them
DE3769287D1 (de) Heilmittel gegen leishmaniose.
EP0459176A3 (en) Oligophosphates with antiviral activity
ITMI931393A0 (it) Procedimento per il funzionamento di un filtro elettrostatico nonche' filtro elettrostatico per l'attuazione del procedimento
NL7604081A (nl) Werkwijze voor de bereiding van zuiver 1.8-dini- troantrachinon.
ES2133573T3 (es) Analogos antiviricos de difluoro estatone.
JPS51134672A (en) Travelling distance counter for automobile

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 646376

Country of ref document: ES